Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia–lymphoma patients with resolved HBV infection following systemic chemotherapy

[1]  S. Iida,et al.  Fatal reactivation of hepatitis B virus infection in a patient with adult T‐cell leukemia–lymphoma receiving the anti‐CC chemokine receptor 4 antibody mogamulizumab , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  Pei-Jer Chen,et al.  Chemotherapy‐induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study , 2014, Hepatology.

[3]  R. Ueda,et al.  Reactivation of hepatitis B virus in a patient with adult T‐cell leukemia–lymphoma receiving the anti‐CC chemokine receptor 4 antibody mogamulizumab , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[4]  M. Mitka.  FDA: Increased HBV reactivation risk with ofatumumab or rituximab. , 2013, JAMA.

[5]  Y. Ishigatsubo,et al.  Successful treatment of a patient with adult T cell leukemia/lymphoma using anti-CC chemokine receptor 4 monoclonal antibody mogamulizumab followed by allogeneic hematopoietic stem cell transplantation , 2013, International Journal of Hematology.

[6]  R. Ueda,et al.  Randomized phase II study of mogamulizumab (KW-0761) plus VCAP-AMP-VECP (mLSG15) versus mLSG15 alone for newly diagnosed aggressive adult T-cell leukemia-lymphoma (ATL). , 2013 .

[7]  R. Ueda,et al.  Prospective Nationwide Observational Study of Hepatitis B Virus (HBV) DNA Monitoring and Preemptive Antiviral Therapy for HBV Reactivation in Patients with B-Cell Non-Hodgkin Lymphoma Following Rituximab Containing Chemotherapy: Results of Interim Analysis. , 2012 .

[8]  A. Ido,et al.  Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy , 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

[9]  R. Ueda,et al.  Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Ueda,et al.  Antibody therapy for Adult T-cell leukemia–lymphoma , 2011, International journal of hematology.

[11]  R. Ueda,et al.  Immunopathogenesis of lymphoma: Focus on CCR4 , 2011, Cancer science.

[12]  K. Ohshima,et al.  Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  K. Shitara,et al.  Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma , 2010, Clinical Cancer Research.

[14]  R. Ueda,et al.  Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy , 2010, Journal of Gastroenterology.

[15]  R. Ueda,et al.  Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma , 2009, International journal of hematology.

[16]  J. Pawlotsky.  EASL Clinical Practice Guidelines. , 2009, Journal of hepatology.

[17]  Edwin P Hui,et al.  Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Yoshio Tateno,et al.  Development and public release of a comprehensive hepatitis virus database , 2008, Hepatology research : the official journal of the Japan Society of Hepatology.

[19]  R. Ueda,et al.  VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Luk,et al.  Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. , 2006, Gastroenterology.

[21]  R. Goldin,et al.  Management of chronic hepatitis B virus infection , 2004 .

[22]  S. Iida,et al.  Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  A. Lok,et al.  Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. , 1991 .